| [ Summary ] |
Some types of immunoadsorbent and cytapheresis technologies have been developed and introduced for clinical applications, in order to the improve removal efficiency of the disease related toxins as well as cells. Immunoadsorption therapies have higher selectivity rates between the normal substances and toxins in the patient's blood than membrane separation therapies, such as plasma exchange (PEX) and double filtration plasmapheresis (DFPP), which depends on the selectivity of their membrane pores. On the other hand, a higher selectivity adsorbent system has a higher cost and reduces the patient population which may use it. New and unique types of apheresis therapies are required and must be cleared for usage through legislation. |